Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Jörge E. Cortes et al.|Cancer Discovery|2018Cited by 570
Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)Veronica Guerra, Koichi Takahashi, Feng Wang et al.|Blood|2019Cited by 8